ProCE Banner Activity

EMPRISE: Efficacy of Empagliflozin vs DPP-4 Inhibitors in Patients With Type 2 Diabetes

Slideset Download
Conference Coverage
The use of empagliflozin in routine care of East Asian patients with type 2 diabetes reduced risk of hospitalization for heart failure, cardiovascular outcomes, and all-cause mortality vs DPP-4 inhibitors.

Released: June 30, 2021

Expiration: June 29, 2022

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Merck

Additional Information

Program Medium

This program has been made available online.